Search results
Sep 26, 2022 · Professor of Medicine, University of Paris. Dr. Leboulch is a Professor of Medicine (emeritus-active) at the University of Paris-Saclay and at Harvard Medical School, where he remains as a Harvard Medical School Corresponding Faculty Member. He has served on the HMS Faculty for 15 years in the Genetics Division of the Brigham & Women's Hospital.
Sep 23, 2005 · Dr. Philippe Leboulch, a highly regarded professor and researcher at Harvard Medical School and Brigham and Women’s Hospital in Boston, will give a talk at The University of Texas at Dallas (UTD) on Friday, Sept. 30, about the possibility of gene therapy cures for sickle cell disease.
Apr 18, 2018 · In the beta thalassemia trial, the successful introduction of the modified globin gene was made possible by a vector, or delivery system, that Philippe Leboulch, one of the co-authors of the...
Dec 11, 2009 · So far this does not appear to be causing any harm, the study leader, Philippe Leboulch of the University of Paris and Harvard Medical School in Boston, told a meeting of the U.S. Recombinant DNA Advisory Committee (RAC).
- Jocelyn Kaiser
- 2009
Mar 2, 2017 · Malik P, Leboulch P. Genetically engineered cures: gene therapy for sickle cell disease. In: Pace B, ed. Renaissance of sickle cell disease research in the genome era.
- Jean-Antoine Ribeil, Salima Hacein-Bey-Abina, Emmanuel Payen, Alessandra Magnani, Michaela Semeraro,...
- 2017
Philippe Leboulch's 197 research works with 14,252 citations and 32,448 reads, including: lovo‐cel gene therapy for Sickle Cell Disease: Treatment process evolution and outcomes in the...
